Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitroglycerin for Esophageal Food Impaction
2023-503983-17-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Aug 2023
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of libervant in Esophageal food impaction (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Resolution of esophageal food impaction without endoscopic removal. Planned start Aug 2023; status: authorised.
02
Drugs
libervant
03
Conditions
Esophageal food impaction
Beyond the preview
Go deeper on 2023-503983-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503983-17-00.